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Abstract
Background: Genetically, colorectal cancers (CRCs) can be subdivided into tumors with chromosomal instability
(CIN) or microsatellite instability (MSI). In both types of CRCs genes that are involved in the degradation of b-
CATENIN are frequently mutated. Whereas in CIN CRCs APC (Adenomatous Polyposis Coli) is affected in most cases,
high grade MSI (MSI-H) CRCs frequently display mutations in various genes, like the APC-, AXIN2-o rCTNNBI (b-
CATENIN) gene itself. Recently in Wilms tumors, WTX (Wilms tumor gene on the X-chromosome) was discovered as
another gene involved in the destruction of b-CATENIN. As the WTX-gene harbors a short T6-microsatellite in its N-
terminal coding region, we hypothesized that frameshift-mutations might occur in MSI-H CRCs in the WTX gene,
thus additionally contributing to the stabilization of b-CATENIN in human CRCs.
Methods: DNA was extracted from 632 formalin-fixed, paraffin-embedded metastatic CRCs (UICCIV) and analyzed
for MSI-H by investigating the stability of the highly sensitive microsatellite markers BAT25 and BAT26 applying
fluorescence capillary electrophoresis (FCE). Then, in the MSI-H cases, well described mutational hot spot regions
from the APC-, AXIN2- and CTNNBI genes were analyzed for genomic alterations by didesoxy-sequencing while the
WTX T6-microsatellite was analyzed by fragment analysis. Additionally, the PCR products of T5-repeats were
subcloned and mutations were validated using didesoxy-sequencing. Furthermore, the KRAS and the BRAF proto-
oncogenes were analyzed for the most common activating mutations applying pyro-sequencing. mRNA expression
of WTX from MSI-H and MSS cases and a panel of colorectal cancer cell lines was investigated using reverse
transcription (RT-) PCR and FCE.
Results: In our cohort of 632 metastatic CRCs (UICCIV) we identified 41 MSI-H cases (6.5%). Two of the 41 MSI-H
cases (4.8%) displayed a frameshift mutation in the T6-repeat resulting in a T5 sequence. Only one case, a male
patient, expressed the mutated WTX gene while being wild type for all other investigated genes.
Conclusion: Mutations in the WTX-gene might compromise the function of the b-CATENIN destruction complex in
only a small fraction of MSI-H CRCs thus contributing to the process of carcinogenesis.
Background
Genetically, colorectal cancers (CRCs) might be subdi-
v i d e di n t ot w og r o u p s .O n eg r o u pi sc h a r a c t e r i z e db y
chromosomal instability (CIN) and follows the classical
multistep carcinogenesis model where mutations result
in the activation of proto-oncogenes (gain of function)
or the inhibition of tumor suppressor genes (loss of
function) by this driving the process of colorectal
carcinogenesis [1]. The other group is characterized by
high grade instability of microsatellites (MSI-H) and can
be subdivided into sporadic and heritable forms and
accounts for approximately 15% of all CRCs. The major-
ity of sporadic MSI-H CRCs is characterized by loss of
expression of the MLH1 (MUT-L homologue 1) gene, a
component of the mismatch repair (MMR) system due
to methylation of its promoter/exon 1 region. These
MSI-H CRCs belong to the CIMP (CpG island methyla-
tor phenotype) and are highly associated with mutations
in the BRAF proto-oncogene (up to 75%) [2]. In con-
trast, the heritable forms of MSI-H CRCs, known as
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harbor mutations in genes of the MMR-system, like
MLH1, MSH2 (MUT-S homologue 2), MSH6 or PMS2
(post mitotic segregation 2). Thus, in MSI-H tumors,
the function of the MMR-system is lost [3]. This in turn
leads to frameshift mutations in microsatellites, which
might contribute to the malignant transformation of
tumor cells when located in the coding sequences of
tumor suppressor genes like the TGFBR2 (TGF-b recep-
tor type 2) [4]. This type of mutation and the associated
occurrence of neoantigenic structures might explain
why sporadic MSI-H CRCs have a better prognosis than
microsatellite stable (MSS) CRCs [5].
Interestingly, the stabilization of b-CATENIN, which is
the executor of the canonical WNT-signaling pathway, is
affected in both, MSI-H and MSS CRCs. In the WT
situation b-CATENIN is earmarked for degradation by a
multi-protein complex assembled of at least APC,
AXIN2, PP2A (pyro-phosphatase 2 A) and GSK3B (glyco-
gen synthase kinase 3b). In MSS CRCs, the stabilization
of b-CATENIN is mostly achieved by mutations in the
tumor suppressor gene APC, which is considered to be
the gatekeeper of colorectal carcinogenesis [1]. In con-
trast in MSI-H CRCs, the stabilization of b-CATENIN
seems to be a later event and is achieved by loss of func-
tion in APC [6-8] in only 14-56%, while in 24% mutations
are found in the AXIN2- [8] or in up to 43% in the
CTNNBI-gene itself, depending on if investigating spora-
dic or heritable cases of CRC [6,8-11]. Expectedly in
MSI-H CRCs, the loss of function mutations in the APC-
and AXIN2-tumor suppressor genes partly results from
frameshift mutations, thus highlighting the causative role
of the MMR system in MSI-H CRCs.
Recently in Wilms tumors, WTX (Wilms Tumor
gene on the X-Chromosome) was discovered as
another component of the b-CATENIN degradation
complex where it directly interacts with b-CATENIN
and APC [12,13]. Moreover, Wilms tumors are often
characterized by a deregulated WNT-signaling pathway
which can be attributed to mutations in the WTX-gene
in 7 to 30% of all cases [14,15]. Due to its location on
the X-chromosome, WTX resembles a one hit tumor
suppressor which has therefore a higher penetrance in
m e nt h a ni nw o m e n .
Because of its role in the degradation of b-CATENIN
and the presence of a short six basepair long T-repeat
(T6) in the N-terminus encoding part of the WTX-gene,
we hypothesized that WTX might also contribute to the
stabilization of b-CATENIN in MSI-H CRCs. Therefore,
we investigated if frameshift mutations are present in
the T6-repeat of the WTX-gene in the MSI-H fraction
of a collection of metastatic CRCs (UICCIV).
Methods
Clinical samples
632 cases of formalin fixed, paraffin-embedded (FFPE)
tissue of metastatic CRCs (UICCIV) were selected for the
investigation. The usage of these cases for scientific rea-
sons was approved by the local ethics committee of the
Medical Faculty of the Ludwig-Maximilians-Universität
München.
DNA and RNA isolation
After removal of paraffin wax using graded xylene- and
alcohol dilutions following routine protocols, tumor
cells were manually dissected from the slides. Subse-
quently, DNA and RNA were extracted using QIAamp
DNA Micro kits or RNeasy FFPE kits (Qiagen, Hilden,
Germany), respectively following the instruction
manuals.
Cell lines, Cell culture and RNA isolation
Cultivated colorectal tumor cell lines RKO, LoVo,
SW480, Caco2, DLD-1, HCT15, HCT116, LS174T and
HT29 were purchased from the ATCC (LGL Promo-
chem GmbH, Wesel, Germany) and maintained in
DMEM (Biochrom, Berlin, Germany) containing 7.5%
(v/v) fetal bovine serum (Biochrom, Berlin, Gemany).
RNA was isolated using RNeasy Mini kits (Qiagen, Hil-
den, Germany) according to the user’s instructions.
PCR, reverse transcription, RT-PCR, fluorescence capillary
electrophoresis (FCE), didesoxy- and pyro-sequencing
For the determination of MSI-H polymerase chain reac-
tions (PCRs) specific for the monomorphic mononucleo-
tide microsatellites BAT25 and BAT26 were done using
1 μl DNA as the template in the presence of 1.5 mM
MgCl2, 200 μM dNTPs (Fermentas, St. Leon, Germany),
400 nM of each of BAT25 or BAT26 specific primer
pairs (Additional file 1, Table S1), respectively together
with 1 U HotStarTaq Polymerase (Qiagen, Hilden,
Germany) following the user’s manual. Male DNA (Pro-
mega, Mannheim, Germany) was used as the template
for positive- and water for negative controls. PCRs spe-
cific for the mutation hot spots of the APC- (exon 15)
[7], AXIN2-( e x o n8 )[ 8 ]a n dCTNNBI- (exon 3) [16,17]
g e n e sa sw e l la st h eT 6-microsatellite of the WTX-gene
were done using the same protocol together with gene-
specific primers (Additional file 1, Table S1). 1 μlo ft h e
final PCR products was used for subsequent sequencing
using BigDye Terminator v1.1 kits (Applied Biosystems,
Darmstadt, Germany) together with appropriate primers
(500 nM, Additional file 1, Table S1). Reactions
were purified using DyeEx v2.0 kits (Qiagen, Hilden,
Germany) following the handbook. 4 μlp u r i f i e d
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Page 2 of 8Table 1 Overview of patient age, gender and mutations found in MSI-H CRCs
Patient ID Age Gender WTX APC
Exon 15
AXIN2
Exon 8
CTNNB1
Exon 3
KRAS
Codon 12/13
BRAF
Codon 600
16 5 m T 5 WT WT WT WT WT
2 n.a. f T5 WT WT WT WT c.1799T>A
35 2 m T 6 WT WT WT WT WT
47 4 m T 6 WT 1 bp del (G)
codon 665
WT WT n.a.
56 8 f T 6 WT WT WT c.35G>A WT
62 8 m T 6 2 bp del (AG)
codon 1462
WT WT WT WT
77 2 f T 6 WT WT WT WT c.1799T>A
86 5 f T 6 n.a. n.a. n.a. WT WT
96 3 f T 6 c.2312A>G
p.E770G
WT WT WT c.1799T>A
10 n.a. m T6 c.2393A>G
p.G797D
WT WT WT c.1799T>A
11 77 f T6 WT WT WT WT WT
12 65 f T6 WT WT WT WT c.1799T>A
13 75 m T6 1 bp ins (A)
codon 1554
WT WT WT c.1799T>A
14 69 f T6 WT c.2062C>T (mut/mut)
p.P687L
c.64G>A
p.V22I
WT WT
15 72 f T6 WT WT WT WT c.1799T>A
16 46 m T6 WT c.2073C>T
p.691Q>STOP
WT WT WT
17 45 f T6 1 bp ins (A)
codon 1554
WT WT WT c.1799T>A
18 42 m T6 WT WT WT WT WT
19 n.a. m T6 WT WT WT WT WT
20 76 m T6 WT WT WT WT c.1799T>A
21 76 m T6 WT WT WT WT WT
22 78 f T6 WT c.2037C>T
p.H679Y and
c.2071C>T
p.691Q>STOP
WT WT WT
23 56 f T6 WT WT c.134C>T
p.S45F
WT c.1799T>A
24 33 m T6 WT WT WT WT WT
25 73 f T6 WT WT WT WT c.1799T>A
26 65 f T6 WT c.2103T>C
p.S701P
WT WT c.1799T>A
27 77 f T6 WT WT WT WT WT
28 69 m T6 WT WT WT WT WT
29 43 m T6 WT WT WT WT WT
30 64 f T6 WT WT WT WT WT
31 43 m T6 WT WT WT WT WT
32 43 m T6 WT WT WT WT WT
33 54 m T6 WT WT WT WT WT
34 66 f T6 WT c.2062C>T
p.P687L
WT WT WT
35 40 f T6 WT WT WT WT WT
36 60 m T6 n.a. n.a. n.a. n.a. WT
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deionized formamide (HiDi, Applied Biosystems, Darm-
stadt, Germany), heated for 2 minutes at 90°C, cooled
down immediately on ice and loaded onto the genetic
analyzer 3130 (Applied Biosystems, Darmstadt, Ger-
many). Results were finally analyzed with the help of the
Sequencing Analysis v5.2- (Applied Biosystems, Darm-
stadt, Germany) and Geneious-software (Biomatters
Ltd., Australia).
For sequencing the fragments generated from the
WTX-gene, PCRs were repeated using the same but
unlabelled primers (Additional file 1, Table S1) as for
the screening for mutations. Resulting PCR products
were subcloned using the CloneJet PCR cloning kit (Fer-
mentas, St. Leon, Germany) according to the user’s
manual and finally sequenced as described above.
For reverse transcription, 1 μg of RNA was converted
into cDNA using QuantiTect Reverse Transcription kits
(Qiagen, Hilden, Germany) in the presence (+) or
absence (-) of reverse transcriptase (RT) following the
user’s manual. For subsequent WTX specific PCRs 1 μl
of a fiftyfold diluted cDNA solution was used as the
template but else applying the same conditions as
described above. RT-PCR specific for the housekeeping
gene ACTB (b-ACTIN, [GenBank: NM_001101]) served
as a control using b-ACTIN specific primers (Additional
file 1, Table S1). Products from RT-PCR were separated
on 2% 0.5 × TBE agarose gels containing 100 ng/ml
ethidium bromide and visualized under UV-light.
For the analysis microsatellite-stability PCR products
were separated by capillary electrophoresis using an ABI
3130 sequencing analyzer by mixing 1 μlo ft h eP C R
products with 18.5 μl highly-deionized formamide
(HiDi) and 0.5 μl of the GeneScan-500 LIZ size standard
(both Applied Biosystems, Darmstadt, Germany), heated
for 2 minutes at 90°C, cooled down immediately on ice,
and subsequently loaded onto the genetic analyzer 3130.
Finally, results were analyzed with the help of the Gene-
Mapper v4.0 software (Applied Biosystems, Darmstadt,
Germany).
Mutations in codons 12 and 13 of the KRAS- and
codon 600 of the BRAF-gene were done as described
[18,19] using Pyromark-Gold reagents (Qiagen, Hilden
Germany) together with the appropriate primers (Addi-
tional file 1, Table S1) following the user’s instructions.
Results
First of all, MSI-H CRCs were identified from our collec-
tion of 632 cases of metastatic CRCs (UICCIV) by inves-
tigating the stability of the highly sensitive and specific
monomorphic mononucleotide markers BAT25 and
BAT26 [20,21] using PCR based fluorescence capillary
electrophoresis (FCE). We detected instability of both
microsatellite markers in 41 out of 632 cases (6.5%) com-
pared to control DNA (Figure 1A, tumor ID #1, #2 (both
MSI-H), #42 (MSS) and Table 1). These 41 cases were
taken for all further investigations as we aimed
to concentrate on WTX frameshift mutations only in
MSI-H CRCs. Second, these cases were analyzed for
mutations in the BRAF- and KRAS-p r o t o - o n c o g e n e s
(Table 1) applying pyro-sequencing. We found two out
of 40 evaluable cases (5%) with activating mutations in
KRAS codons12 and 13 and 12 out of 39 cases (30.8%)
with an activating mutation in codon 600 of the BRAF
gene (p.V600E). Third, WTX frameshift mutations were
found in 2 out of the 41 investigated MSI-H CRCs (4.9%)
as shown by FCE and resulted in a T5-repeat (Figure 1B,
tumor ID #1, #2), while no such mutations were present
in MSS CRCs (Figure 1B, ID #42). These findings were
further confirmed by subcloning the truncated WTX
PCR products and subsequent didesoxy-sequencing. Both
approaches also revealed signals from the wild type T6-
repeat in both cases (not shown for direct sequencing),
which probably stem from contaminations with normal
tissue, as well as signals derived from the second, intact
X-chromosome, the latter of course only in case of
female patients. The detected frameshift leads to a stop
codon (TGA) at position 621 of the coding sequence of
the WTX-gene, which is of 3.408 bp in length (GenBank:
NM_152424). When expressed, such mutated WTX
alleles will inevitably result in a truncated protein of 207
instead of wild typic 1.135 amino acids. Such a protein
will have no functional properties with respect to
the degradation of b-CATENIN, since the APC and
Table 1 Overview of patient age, gender and mutations found in MSI-H CRCs (Continued)
37 63 f T6 WT WT WT c.35G>A WT
38 73 m T6 WT WT WT WT WT
39 72 f T6 WT c.2077A>G
p.H692R
WT WT WT
40 65 f T6 n.a. n.a. n.a. WT n.a.
41 52 m T6 c.2626C>T
p.876R>STOP
and
2 bp del (AG)
codon 1462
WT WT WT WT
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ally of amino acid 207, namely positions 307-789 and in
the C-terminus, respectively [12,13]. Tumor ID #2 was
additionally characterized by a mutation in the BRAF
gene (Table 1). Fourth, we wanted to increase the evi-
dence that the WTX mutations might have a functional
relevance for the stabilization of b-CATENIN in the con-
text of the other members of the WNT signaling pathway
APC, AXIN2 and CTNNB1, which have been described to
be mutated in MSI-H CRCs. Therefore, we investigated
the described mutational hot spot regions of these three
genes in the 41 MSI-H CRCs [7,8,16,17] by direct dide-
soxy-sequencing (Table 1). Mutations in the APC gene
were detected in 6 out of 38 evaluable cases (15.8%), in
the AXIN2-gene in 7 of 38 (18.4%) and in the CTNNBI-
gene in 2 of 38 (5.3%) cases. As far as to our knowledge,
some of the detected mutations have not been described
previously and thus their functional consequences remain
to be determined. Importantly, however, we could not
find any additional mutations in the two tumors display-
ing the WTX T5 frameshift. Fifth, we analyzed the expres-
sion of WTX mRNAs in the tumors of the patients with
WTX frameshift mutations in order to assess whether
these might be of functional relevance for the stabiliza-
tion of b-CATENIN. Due to the clonal origin of cancers
and the fact that only one X-chromosome is transcrip-
tionally active in women whereas men carry only a single
X-chromosome, mutations in X-chromosomal encoded
genes like the WTX-gene will have a direct functional
consequence known as haplo-insufficiency when being
expressed. Thus, we checked, first of all, if WTX is com-
monly expressed in CRCs and especially in the patients
carrying T5-repeats in their WTX-genes. The tumors of
both patients expressed WTX mRNA (Figure 2A, tumor
ID #1 and #2), as did MSI-H tumors from patients with
wild type WTX genes (Additional file 2, Figure S1 A
patient ID #4 - #6) or tumors from MSS CRCs (Figure
2A, tumor ID #42 and Additional file 2, Figure S1 A,
tumor ID #43 and #44), as well as a panel of cultivated
colorectal tumor cell lines (Additional file 2, Figure S1
B). Next, we investigated the length of the T6-m i c r o s a -
tellite in the WTX-mRNA. We found that only one of the
two tumors (ID #1, a male patient) harbored the T5-fra-
meshift mutation on the transcript level (Figure 2B,
tumor ID #1) and thus inevitably also on the protein
level. However, this latter fact could not be verified
immunohistochemically due to lack of specific antibodies
distinguishing between wild type and mutated WTX pro-
tein. The T5-repeat containing tumor of the female
patient (ID #2) expressed wild-type WTX-mRNA, indi-
cating that the mutated gene was located on the inacti-
vated X-chromosome.
Discussion
MSI-H CRCs constitute approximately 15% of
all CRCs [3] and are generally considered to be
Figure 1 MSI-H colorectal tumors display frameshift mutations in the T6-microsatellite of the WTX-gene. (A) Genomic DNA from 632
patients with metastatic CRC (UICCIV) was analyzed for the presence of MSI-H with the help of the two monomorphic microsatellite markers
BAT25 and BAT26. Shown are representative results from two CRCs with MSI-H (ID #1, #2) and one CRC with MSS (ID #42). (B) Two tumors of the
41 MSI-H cases of CRCs harbored frameshift mutations in the coding sequence of the T6-repeat of the WTX-gene resulting in the occurrence of a
T5-repeat (ID #1 and #2) compared to only wild type T6-repeats in tumors with MSS CRCs (ID #3). Left: shown by FCE, right: shown by direct
sequencing.
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the MSS type [5]. This is reflected by the fact that
only 7.9% of all MSI-H CRCs show progression to a
metastatic state (UICCIV), while 27.9% of MSS cases
succeed in forming distant metastases [22]. Thus, the
proportion of MSI-H CRCs among tumors in UICCIV
has been found to be less compared with the mean
value of 15% in all stages (UICCI - UICCIV) [23]
which is in support with 41 MSI-H cases found in
632 UICCIV cases of CRCs (6.5%). These results were
obtained using the two mononucleotide markers
BAT25 and BAT26 instead of the five marker set
recommended by the Bethesda guidelines from the
National Cancer Institute [20] because these two mar-
kers were shown to be of almost the same diagnostic
value as all five NCI markers in combination [21].
Furthermore, due to their monomorphic character,
usage of BAT25 and BAT26 makes a comparison of
normal tissue dispensable.
The difference in clinical behavior of colorectal MSI-H
and MSS tumors is also reflected by differences in the
mechanisms of genetic instability. MSS CRCs usually
mutate the APC tumor suppressor gene by gross dele-
tions in the genome known as loss of heterozygosity
(LOH) or point mutations [24]. As this occurs as the
entry mutation in the process of colorectal carcinogen-
esis APC is here known as the gatekeeper [1]. In con-
trast, MSI-H CRCs seem to evolve via a different
pathway as mutations in the BRAF or less often KRAS
proto-oncogene occur early [3]. Our findings show that
in UICCIV less tumors carry BRAF gene mutations
(28% compared with up to 75% in MSI-H tumors of all
stages [2]) indicating that in MSI-H tumors BRAF muta-
tions might be somehow protective for progression into
UICCIV. Alternatively, the amount of heritable HNPCC
tumors might be higher in our collection which do not
show mutations in the BRAF gene [2]. Due to changes
in the cellular methylation system in sporadic MSI-H
tumors the expression of several tumor suppressor
genes is turned off due to methylation of its promoter/
exon1. This also seems to be the cause for the loss of
the expression of the MLH1 (MUT-L homologue) gene.
As a consequence, instability of microsatellites occurs
which affects in a second wave of mutations compo-
nents of the WNT-signaling pathway, like the APC-,
or the AXIN2-gene and, as shown here in a small group
of cases, additionally in the WTX-gene. Since we con-
centrated on defects leading to the stabilization of b-
CATENIN in MSI-H CRCs, a collection of UICCIV
tumors was used because it was expected that later
states should contain most if not all mutations leading
to the stabilization of b-CATENIN. One study analyzed
in a group of 45 MSI-H CRCs the occurrence of muta-
tions in the three genes encoding AXIN2 (11/45 -
24.4%), APC (4/28 - 14.3%) and CTNNBI (5/45 - 11.1%)
[8], thus assigning approximately 50% of MSI-H CRCs
with defects in components of the WNT signaling path-
way. Assuming that mutations in the WNT-signaling
pathway might also be important in MSI-H tumors, it
suggests that additional mechanisms might contribute to
the stabilization of b-CATENIN in this tumor entity.
The situation turns out to be even more complex as
heritable and sporadic forms of tumors display partly
great differences in their mutational spectrum as e.g.
shown for the CTNNB1 gene where sporadic tumors do
not display mutation [11] compared to 43% in heritable
HNPCC cases [10]. Analyzing our mixed collection of
UICCIV MSI-H CRCs, we found 15 out 38 evaluable
cases (39.5%) with mutations in the established compo-
nents of the WNT signaling pathway. Alternatively, this
might be a stage specific effect as it was shown that
Figure 2 Frameshift mutations in the WTX-gene are expressed
on the mRNA level. (A) CRCs (ID #1, #2 and #42) expressed WTX
mRNA. (B) One of the two CRCs with MSI-H and a genomic
frameshift mutation in the WTX-gene displayed expression of the
mutated allele on the level of mRNA (ID #1) whereas the other
tumor (ID #2) as well as MSS-CRCs (ID #42) harbored wild type
mRNA indicated by the presence of only T6-repeats.
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group than MSS tumors which is not the case in the
other stages (UICCI - UICCIII) thus indicating a special
biology of MSI-H tumors in UICCIV [22]. Here, we add
frameshift mutations in the recently identified WTX-
gene, a component of the b-CATENIN degradation
complex [13], as an additional mechanism which were
found at a frequency of 2/41 among MSI-H cases
(4.9%). This frameshift occurred in a 6 thymidine repeat
that is located in the N-terminal coding region giving
rise to an unfunctional gene product when being tran-
scribed as shown here and translated due to the absence
of the APC- and b-CATENIN interaction domains
[12,13]. Moreover, we detected several monorepeats of
five basepairs in length distributed over the WTX open
reading frame which we did not investigate for instabil-
ity because they are to small to be targets for microsa-
tellite frameshifts [25].
In general a rate of two out of 41 is very low but it is
misleading to conclude from mutation rates on the
importance of genes as even intronic regions display
mutation rates of 54.2% which are known to be only pas-
senger mutations [26]. Moreover, even high mutation fre-
quencies of 39% in the TCF4 gene (T-cell transcription
factor 4) [27] which has an important role in WNT-sig-
naling are not warranting that the mutations might have
a physiologic effect [28]. Thus, the finding that 1 patient
(2.5%) expressed the genetic alteration on the mRNA
level may be an indicator that alterations in the WTX-
gene might have a functional role for the stabilization of
b-CATENIN and have in this case the status of a driver
mutation. This accounts especially in the context of
a b s e n to t h e rm u t a t i o n si nt h eW N Tp a t h w a y( T a b l e1 )
and when considering that this patient with tumor ID #1
was a 65 years old man with probably a sporadic tumor
and that WTX is located on the X-chromosome. More-
over, our mutation frequency is consistent with another
study, which detected only a single mutation in 47 CRCs
(2.1%), irrespective of the MSI status [29]. While the
functional consequene of this described point mutation is
unknown, this and our work at least indicate that muta-
tions in WTX might be involved in colorectal carcinogen-
esis in a small proportion of both, MSI-H as well as MSS
tumors. Interestingly, our result that the tumor of a
female patient displayed the mutation in the WTX-gene
on the transcriptionally inactive X-chromosome is in sup-
port with findings from Wilms tumors where mutations
of the WTX-gene were also found on the inactivated
X-chromosome in women [14]. Obviously, larger cohorts
are needed for definitively answering the open questions
about the frequency of WTX-gene mutations and
the prevalence of mutations on the inactivated X-
chromosome in female patients.
Conclusion
Taking together, we demonstrate that mutations in the
WTX- g e n em i g h tp l a yar o l ei nt h ep r o c e s so fM S I - H
colorectal carcinogenesis in a small subgroup of these
tumors as has been modeled for Wilms Tumors before
[30]. This implies that WTX-gene mutations should be
reconsidered in future studies dealing with MSI-H
CRCs, especially in the context of the other known
mutations leading to stabilization of b-CATENIN.
Importantly, a functional role of these mutations for the
process of colorectal carcinogenesis has to be investi-
gated in further works in the future.
Additional material
Additional file 1: Table S1 Oligonucleotides used in this study.
Additional file 2: Figure S1 CRCs as well as colorectal tumor cell
lines express WTX mRNA. (A) All cases of CRCs tested expressed WTX
mRNA irrespective of being MSI-H (ID #1, #2 and #4 to #6) or MSS (ID
#42 to #44). (B) A panel of cultivated CRC cell lines also expressed WTX
mRNA. PCR specific for the housekeeping gene ACTB (b-ACTIN) served as
a control.
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